Physician profile
Terri Lo
NPI 1205267895
$4,531.40
in general payments reported to CMS, 2019-2025
29 companies · $2,131 in 2025
The $2,131 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $150 · 2022: $156 · 2023: $1,038 · 2024: $1,057 · 2025: $2,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,224 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,224.42 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $534.79 | 2023-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abbott Laboratories | $477.25 | 2023-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Infinity, Alinity |
| Glaxosmithkline, LLC. | $421.32 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Teva Pharmaceuticals USA, INC. | $362.04 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alnylam Pharmaceuticals INC. | $293.71 | 2025 | Amvuttra, Onpattro |
| Novo Nordisk INC | $246.27 | 2024-2025 | Ozempic |
| Regeneron Healthcare Solutions, INC. | $227.91 | 2024 | Dupixent |
| Genzyme Corporation | $226.28 | 2025 | |
| Abbvie INC. | $162.60 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $152.27 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.80 | 2021-2022 | |
| Madrigal Pharmaceuticals | $145.18 | 2025 | Rezdiffra |
| Silk Road Medical, INC. | $133.33 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Janssen Scientific Affairs, LLC | $125.00 | 2023 | |
| Boston Scientific Corporation | $125.00 | 2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $124.98 | 2024 | |
| Shield Therapeutics INC | $123.79 | 2023 | Accrufer |
| Novartis Pharmaceuticals Corporation | $98.39 | 2025 | |
| Medtronic, INC. | $97.46 | 2024 | Intellis Adaptivestim |
| Scynexis, INC. | $83.33 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $50.10 | 2023 | |
| Merck Sharp & Dohme LLC | $28.08 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Amgen INC. | $25.45 | 2025 | Evenity |
| Amarin Pharma, INC. | $24.46 | 2022 | |
| Vivus LLC | $23.73 | 2025 | Pancreaze |
| Agios Pharmaceuticals, INC. | $22.96 | 2025 | Pyrukynd |
| Phathom Pharmaceuticals, INC. | $15.80 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $15.30 | 2021 | |
| Hollister Incorporated | $14.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terri Lo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.